

**TCTR ID : TCTR20180711003**

**Overall Recruitment Status :** Active, not recruiting

**OTHER ID :**

**Prospective registration**  
**This protocol was registered before enrollment of the first participant.**

---

**Tracking Information**

First Submitted Date : 11 July 2018  
First Posted Date : 11 July 2018  
Last Update Posted Date : 04 February 2022

---

**Title**

Public Title : A prospective randomised trial examining the impact of an intensive educational intervention versus usual care on anticoagulation therapy control based on SAME-TT2R2 score guided strategy in anticoagulant-naïve Thai patients with atrial fibrillation

Acronym : TREATS-AF

Scientific Title : A prospective randomised trial examining the impact of an intensive educational intervention versus usual care on anticoagulation therapy control based on SAME-TT2R2 score guided strategy in anticoagulant-naïve Thai patients with atrial fibrillation

Sponsor ID/ IRB ID/ EC ID : CREC053/62BRm

Registration Site : Thai Clinical Trials Registry

URL : <https://www.thaiclinicaltrials.org/show/TCTR20180711003>

Secondary ID : No Secondary ID

Other Grant/Funding Number; Grantor or Funder : NEWTON FUND DBG6180009

---

**Ethics Review**

1. Board Approval : Submitted, approved

Approval Number : COA-CREC 007/2020

Date of Approval : 08 January 2020

Board Name : Central Research Ethics Committee

Board Affiliation : National Research Council of Thailand

Board Contact : Business Phone : 6625790117 Ext. No Data

Business Email : timpika.nimkham.crec@gmail.com

Business Address : Central Research Ethics Committee office 5th Floor The National Research Council of Thailand building 2196 Phaholyothin Road, Ladyao, Chatuchak, Bangkok 10900 Thailand

---

**Sponsor**

Source(s) of Monetary or Material Supports : Faculty of Medicine, Chiang Mai University

Study Primary Sponsor : Faculty of Medicine, Chiang Mai University

Responsible Party : Name/Official Title : Arintaya Phrommintikul

Organization : Faculty of Medicine, Chiang Mai University

Phone : 6653936716 Ext. No Data

Email : arintayap@yahoo.com

Study Secondary Sponsor : The Thailand Research Fund

---

**Protocol Synopsis**

Protocol Synopsis : Anticoagulants are needed to prevent stroke and death in patients with atrial fibrillation (AF). AF is the world's most common form of irregular heartbeat. Warfarin is the most commonly used anticoagulant in Thailand to prevent strokes, but because it is influenced by many diet and patient factors it can be difficult to achieve good anticoagulation control. Our aim is to conduct a randomized controlled trial (RCT) in Thai AF patients who have not used an anticoagulant before to evaluate the use of a simple clinical prediction score (SAME TT2R2) to help identify those patients likely to have a good response to anticoagulation with warfarin, compared with usual care. This is open-label, RCT 9 month recruitment period, 12 months follow up. Eligible participants will be randomised to one of 2 groups: Usual care vs. SAME TT2R2 score guided warfarin.

**URL not available**

---

**Health Conditions**

Health Condition(s) or Problem(s) Studied : New Atrial Fibrillation patients

Keywords : Atrial Fibrillation SAME-TT2R2 score Intensive educational intervention Anticoagulation therapy The time in therapeutic range

## Eligibility

Inclusion Criteria : Inclusion criteria:  
Patient must meet all of the following inclusion criteria to be eligible for study:  
(1) More than 18 years of age  
(2) Newly diagnosed non-valvular AF patients  
(3) ECG-documented AF  
(4) Warfarin-eligible (men with CHA2DS2VASc score more than 1; women with CHA2DS2VASc score more than 2)  
(5) Warfarin-naïve (No treatment with warfarin within the past 12 months, treatment may have started within the prior 28 days from randomisation)  
(6) Able to comply with scheduled visits, treatment plan and laboratory tests  
(7) Able to give informed consent and comply with study protocol (with support of a carer)

Gender : Both

Age Limit : Minimum : 18 Years Maximum : N/A (No limit)

Exclusion Criteria : The subjects present with the following criteria will not be included:  
(1) Any contraindication to oral anticoagulants  
(2) Prosthetic cardiac valve or significant valvular heart disease with an indication for heart surgery  
(3) Likelihood of intermittent or permanent discontinuation of warfarin during follow-up (e.g., major surgery or post-AF ablation)  
(4) Known active malignancy  
(5) Diagnosed cognitive impairment  
(6) Any disease likely to cause death within 12 months  
(7) Unable to provide written informed consent.

Accept Healthy Volunteers : No

## Status

Overall Recruitment Status : Active, not recruiting

Key Trial Dates	Study Start Date (First enrollment) : 31 January 2020	Indicate Type : Actual
	Completion Date (Last subject, Last visit) : 15 November 2022	Indicate Type : Anticipated
	Study Completion Date : 31 December 2022	Indicate Type : Anticipated

## Design

Study Type : Interventional

Primary Purpose : Treatment

Study Phase : Phase 0

Intervention Model : Parallel

Number of Arms : 2

Masking : Open Label

Allocation : Randomized

Control : No treatment / Standard of care

Study Endpoint Classification : Efficacy Study

Sample size

Planned sample size : 320

Intervention Arm 1

Intervention name : SAME-TT2R2 score guided Oral anticoagulation (OAC)

Intervention Type : Active Comparator

Intervention Classification : Other

Intervention Description : The SAME-TT2R2 score was effective in predicting warfarin control whereby patients with a score > 2 had poor control.

Intervention Arm 2

Intervention name : usual care  
Intervention Type : No Intervention  
Intervention Classification : No treatment  
Intervention Description : Usual care no other intervention.

## Outcome

### Primary Outcome

1. Outcome Name : Time in the Therapeutic Range (TTR)  
Metric / Method of measurement : INR level  
Time point : 12 month

### Secondary Outcome

1. Outcome Name : Time in the Therapeutic Range (TTR)  
Metric / Method of measurement : INR level  
Time point : 6 month

2. Outcome Name : Thromboembolic and bleeding events  
Metric / Method of measurement : Number of thromboembolic and bleeding events  
Time point : 12 month

3. Outcome Name : major adverse cardiovascular events (MACE)  
Metric / Method of measurement : Number of major adverse cardiovascular events (MACE)  
Time point : 12 month

4. Outcome Name : Atrial Fibrillation Knowledge  
Metric / Method of measurement : Questionnaires  
Time point : 6 and 12 month

5. Outcome Name : Economic: Cost Effectiveness  
Metric / Method of measurement : Questionnaires  
Time point : 6 and 12 month

6. Outcome Name : Economic: Quality of life  
Metric / Method of measurement : EQ5D5L questionnaires  
Time point : 6 and 12 month

7. Outcome Name : Qualitative: Patient Satisfaction  
Metric / Method of measurement : Patient interview analyse by frame matrices  
Time point : 6 month

## Location

### Section A : Central Contact

Central Contact	First Name : Arintaya Degree : M.D.	Middle Name : Phone : 66 5393 6716 Ext. : No Data	Last Name : Phrommintikul Email : arintayap@yahoo.com
Central Contact Backup	First Name : Siriluck Degree : R.N.	Middle Name : Phone : 66 5393 6716 Ext. : No Data	Lastname : Gunaparn Email : sgunaparn@gmail.com

### Section B Facility Information and Contact

1. Site Name : Faculty of Medicine, Chiang Mai University  
City : Muang Chiang Mai  
Country : Thailand  
State/Province : Chiang Mai  
Recruitment Status : Completed  
Postal Code : 50200

<b>Facility Contact</b>	First Name : Arintaya Degree : M.D.	Middle Name : Phone : 66 5393 6716 Ext. : No Data	Last Name : Phrommintikul Email : arintayap@yahoo.com
<b>Facility Contact Backup</b>	First Name : Siriluck Degree : R.N.	Middle Name : Phone : 66 5393 6716 Ext. : No Data	Last Name : Gunaparn Email : sgunaparn@gmail.com
<b>Investigator Name</b>	First Name : Arintaya Degree : M.D.	Middle Name : Role : Principal Investigator	Last Name : Phrommintikul

### Section C : Contact for Public Queries (Responsible Person)

First Name : Arintaya	Middle Name :	Last Name : Phrommintikul
-----------------------	---------------	---------------------------

Degree : M.D. Phone : 66 5393 6716 Ext. : No Data Email : arintayap@yahoo.com  
Postal Address : Department of Internal Medicine, Faculty of Medicine, Chiang Mai UniversityMuang Chiang Mai  
State/Province : Chiang Mai Postal Code : 50200  
Country : Thailand Official Role : Study Principal Investigator  
Organization Affiliation : Faculty of Medicine, Chiang Mai University

**Section D : Contact for Scientific Queries (Responsible Person)**

First Name : Arintaya Middle Name : Last Name : Phrommintikul  
Degree : M.D. Phone : 66 5393 6716 Ext. : No Data Email : arintayap@yahoo.com  
Postal Address : Department of Internal Medicine, Faculty of Medicine, Chiang Mai UniversityMuang Chiang Mai  
State/Province : Chiang Mai Postal Code : 50200  
Country : Thailand Official Role : Study Principal Investigator  
Organization Affiliation : Faculty of Medicine, Chiang Mai University

---

**Deidentified Individual Participant-level Data Sharing**

Plan to share IPD : Yes  
Plan description : 2 years after publication

---

**Publication from this study**

MEDLINE Identifier : No Data  
URL link to full text publication : No Data

---